About this trial
Sarcopenia is a complex syndrome characterized by progressive and generalized loss of skeletal muscle mass and strength. In patients with cancer, sarcopenia is associated with poorer prognosis, increased treatment-related toxicity, higher postoperative complication rates, reduced response to therapy, and decreased quality of life. Importantly, sarcopenia may be present even in patients with preserved nutritional status or overweight.
Patients with gastrointestinal cancers are at particularly high risk of developing sarcopenia, both as a consequence of the malignant disease itself and as a result of systemic anticancer treatment. Early identification of patients at risk is therefore essential in order to enable timely nutritional and supportive interventions.
The aim of this study is to evaluate the proportion of patients with gastrointestinal cancer who screen positive for sarcopenia risk using the SARC-F questionnaire before the start of systemic treatment and during treatment. Patients with a positive screening result will be referred for further clinical nutritional assessment and managed according to a multidisciplinary approach.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
Prior systemic therapy or radiotherapy for head and neck cancer.
Trial design
Single group
Treatments tested in this trial
Cetuximab (CRC)
DrugCetuximab is administered in combination with induction chemotherapy followed by concurrent chemoradiotherapy, according to the study protocol.
Treatment groups
Trial outcomes
Primary outcomes
Overall Survival
Overall survival is defined as the time from study enrollment to death from any cause
Sponsors and contacts
Click on the lead sponsor to view all of their trials.